ImmunityBio
IBRX

$3.38

0%

Market Cap: $2.35B

About: ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: United states and Europe. Key revenue is generated from Europe.

Employees: 622

Healthcare Biological Products, Except Diagnostic Substances

0

Funds holding %

of 6,686 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

123% more first-time investments, than exits

New positions opened: 49 | Existing positions closed: 22

33% more repeat investments, than reductions

Existing positions increased: 61 | Existing positions reduced: 46

17% more funds holding

Funds holding: 161 [Q1] → 188 (+27) [Q2]

8% more capital invested

Capital invested by funds: $359M [Q1] → $388M (+$29.6M) [Q2]

1.02% less ownership

Funds ownership: 9.9% [Q1] → 8.88% (-1.02%) [Q2]

31% less call options, than puts

Call options by funds: $24.8M | Put options by funds: $35.9M

See Fund Rankings

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target

$4.75

41%

upside

Avg. target

$4.75

41%

upside

High target

$4.75

41%

upside

1 analyst rating

0 positive

0%

1 neutral

100%

0 negative

0%

Piper Sandler

Joseph Catanzaro

32% 1-year accuracy

8 / 25 met price target

41%upside

$4.75

Neutral

Maintained

19 Aug 2024

See Analyst Rankings

Financial journalist opinion

Based on 4 articles about IBRX published over the past 30 days

Top 3 Health Care Stocks That Are Set To Fly This Quarter

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Top 3 Health Care Stocks That Are Set To Fly This Quarter

ImmunityBio: Anktiva's Launch Progresses - Bladder Cancer Drug May Be 'Real Deal'

ImmunityBio received FDA approval for ANKTIVA plus BCG for BCG-unresponsive bladder cancer in April. The drug has a unique mechanism of action. Immunity's early launch progress of Anktiva shows promising market access initiatives, but financial concerns remain due to high R&D costs. Analysts project peak revenues of ~$900m by 2028 for Anktiva, although at present, Immunity's pricing of the drug is a little hard to understand.

ImmunityBio: Anktiva's Launch Progresses - Bladder Cancer Drug May Be 'Real Deal'

Zacks Investment Research

ImmunityBio (IBRX) Reports Q2 Loss, Lags Revenue Estimates

ImmunityBio (IBRX) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.28 per share a year ago.

ImmunityBio (IBRX) Reports Q2 Loss, Lags Revenue Estimates

ImmunityBio's ANKTIVA® Now Covered By More Than a Dozen Insurance Plans Representing Over 100 Million Lives Within Months of FDA Approval

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), today announced significant progress in market access, making ANKTIVA® (nogapendekin alfa inbakicept-pmln) widely available to patients through both commercial and government insurance programs. The company also announced plans to expand its bladder cancer program globally, notably in the European Union and India. Commercial Update ImmunityBio's commercial team continues to execute on key market access initiatives, which ha.

ImmunityBio's ANKTIVA® Now Covered By More Than a Dozen Insurance Plans Representing Over 100 Million Lives Within Months of FDA Approval

ImmunityBio Announces Study of ANKTIVA® in Combination with the AdHER2DC Cancer Vaccine as a Potential Therapy to Control Endometrial Cancer

CULVER CITY, Calif.--(BUSINESS WIRE)--Immunotherapy company ImmunityBio, Inc. (NASDAQ: IBRX), today announced the opening of a clinical trial to study ANKTIVA® (nogapendekin alfa inbakicept-pmln) together with the investigational AdHER2DC vaccine (autologous dendritic cells transduced with HER2 expressing adenovirus), in individuals with HER2-expressing endometrial cancer. It marks the latest trial involving ANKTIVA, the company's IL-15 superagonist immune enhancer, to evaluate ANKTIVA as an ag.

ImmunityBio Announces Study of ANKTIVA® in Combination with the AdHER2DC Cancer Vaccine as a Potential Therapy to Control Endometrial Cancer

Kuehn Law Encourages Investors of ImmunityBio, Inc. to Contact Law Firm

NEW YORK , July 25, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of ImmunityBio, Inc. (NASDAQ: IBRX) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing.

Kuehn Law Encourages Investors of ImmunityBio, Inc. to Contact Law Firm

7 Biotech Stocks to Keep on Your Clinical Radar

Initially, I had every intention to write a cookie-cutter assessment of intriguing biotech stocks; that is, I wanted to say that enterprises within this specialized healthcare field will always be relevant as humans leverage advanced innovations to address vexing conditions and diseases. That remains true.

7 Biotech Stocks to Keep on Your Clinical Radar

3 Top Cancer Treatment Stocks to Buy Now

Discovering and developing a cancer drug that can treat many types of the disease can be extremely lucrative. Consider that one such drug, Merck's (NYSE: MRK ) Keytruda, generated $25 billion in revenue for the pharmaceutical giant last year.

3 Top Cancer Treatment Stocks to Buy Now

Zacks Investment Research

ImmunityBio (IBRX) Gains 17% in the Past Week: Here's Why

ImmunityBio (IBRX) rises 17% in the past week as it announces insurance coverage as well as the treatment of the first patients with its newly approved bladder cancer immunotherapy, Anktiva.

ImmunityBio (IBRX) Gains 17% in the Past Week: Here's Why

ImmunityBio: Positive Near-Term Catalysts Create Strong Short Squeeze Potential

IBRX has a short interest % of the float of 33%, superior to GME at 21%. Investors should keep an eye on it for short squeeze-fueled volatility. IBRX has positive catalysts on the horizon, such as the commercialization of Anktiva for bladder cancer and the FDA review of Anktiva for lung cancer. IBRX has an overleveraged balance sheet, but the billionaire "face" of the company, Patrick Soon-Shiong, will ensure it remains solvent. Any capital raises from him likely won't increase the float.

ImmunityBio: Positive Near-Term Catalysts Create Strong Short Squeeze Potential

See News Rankings